Bristol-Myers Squibb Given “Outperform” Rating at Cowen and Company (BMY)
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “outperform” rating restated by equities researchers at Cowen and Company in a research report issued on Thursday, Analyst Ratings.Net reports. They currently have a $59.00 price target on the stock. Cowen and Company’s target price would indicate a potential upside of 13.20% from the stock’s previous close.
A number of other firms have also recently commented on BMY. Analysts at Leerink Swann reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. They now have a $62.00 price target on the stock. Separately, analysts at William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Thursday. Finally, analysts at BMO Capital Markets downgraded shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research note on Thursday. They now have a $55.00 price target on the stock, down previously from $60.00. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $56.15.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 52.12 on Thursday. Bristol-Myers Squibb has a 52 week low of $41.11 and a 52 week high of $57.49. The stock has a 50-day moving average of $50.52 and a 200-day moving average of $52.20. The company has a market cap of $86.372 billion and a P/E ratio of 30.17.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.43 by $0.03. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter last year, the company posted $0.41 earnings per share. Bristol-Myers Squibb’s revenue was down .5% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb will post $1.79 earnings per share for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.